Ionis Pharmaceuticals
Business Services · California, United States · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
2855 Gazelle Ct, Carlsbad, California, 9...Phone Number
(760) 931-9200Website
www.ionis.comRevenue
$1.1 BillionStock Symbol
IONSIndustry
ZI Rank: 3
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
6
7
2
2
3
3
About Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a pioneering commercial-stage biotechnology company specializing in the discovery and development of RNA-targeted medicines, headquartered in Carlsbad, California. Founded in 1989 by Stanley Crooke as ISIS Pharmaceuticals and renamed Ionis in December 2015, the publicly traded company has established itself as an industry leader in antisense therapy technology, as well as RNA interference and CRISPR therapeutics. Ionis focuses on developing innovative treatments for serious diseases including cardiovascular, metabolic, neurological, and rare genetic conditions, as well as cancer. The company's proprietary antisense technology platform enables the discovery of first-in-class and best-in-class medicines that target RNA to modulate protein production.Explore more
Ionis Pharmaceuticals Org Chart
Get the full picture
Sign in to uncover key details.
BS
Vice President, Investor Relations
DC
Vice President, Tax & Treasury
EK
Vice President, Accounting
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Ionis Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Ionis Pharmaceuticals launches new products
Earning: See what the market has to say on Ionis Pharmaceuticals recently announced quarterly report
Ionis Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Ionis Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once Ionis Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Ionis Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Ionis Pharmaceuticals
Check out if Ionis Pharmaceuticals is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to Ionis Pharmaceuticals
Compare insights from companies similar to Ionis Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Ionis Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Ionis Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Ionis Pharmaceuticals.
Ionis Pharmaceuticals financials insights
Gather financial insights about Ionis Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2012
Debt
$201.3M
Ionis Pharmaceuticals Tech Stack
A closer look at the technologies used by Ionis Pharmaceuticals
See more technologies
Most Recent Scoops
Partnership
Ionis Pharmaceuticals has entered into an agreement with Recordati to bring Zilganirsen to people with Alexander disease outside the U.S., with Recordati planning to file for regulatory approval in the EU and Japan next year, followed by additional global filings.
Partnership
Partnership
Ionis Pharmaceuticals has announced that Bepirovirsen, its medicine for the treatment of chronic hepatitis B partnered with GSK, is on track for approval in the U.S. and Japan later this year, with multiple additional global approvals anticipated next year, based on positive Phase 3 B-Well study data demonstrating unprecedented functional cure rates.
Pharmaceuticals
Product Launch
Ionis Pharmaceuticals has announced plans to launch Zilganirsen for the treatment of Alexander disease later this year, following FDA priority review with a PDUFA date of September 22, with an expanded access program underway and commercial preparations on track.
Product Launch, Pharmaceuticals
Product Launch
Ionis Pharmaceuticals has announced the launch of Trengulza, available in 50 mg and 80 mg doses for the treatment of severe hypertriglyceridemia (SHTG), with both doses entering the channel within approximately one week of approval. The omnichannel launch campaign has produced strong engagement, rapidly building awareness of SHTG, APOC3 biology, and Trengulza among top physician targets.
Pharmaceuticals
Project
Pharmaceuticals
Ionis Pharmaceuticals News & Media
Ionis Pharmaceuticals Q2 Earnings Call Highlights
Ionis Pharmaceuticals (NASDAQ:IONS) reported second-quarter revenue growth driven by commercial products and partnered research programs, while highlighting the recent U.S. approval and early launch progress for TRYNGOLZA in severe hypertriglyceridemia. Chief Executive Officer Brett Monia said theIonis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% - HBSS
SAN FRANCISCO, July 23, 2026 /PRNewswire/ -- Investors in Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) saw the price of their shares plunge $20.19 (-23%) on July 9, 2026 after the commercial stage biotech company and its partner (AstraZeneca) announced that a late-stage trial for an...Ionis Pharmaceuticals, Inc. (IONS) Faces Investor Scrutiny After Surprise Trial Failure Drives Stock Down 23% – HBSS
Investors who lost money in IONS after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman.Panic grips Ionis Pharmaceuticals investors amid bad news spree
A single failed trial can undo years of work in one trading session, and Ionis Pharmaceuticals (IONS) just went through both consecutively. Ionis Pharmaceuticals lost nearly a quarter of its value on July 9 after its heart drug Wainua failed to meet the primary goal of a late-stage trial. The ...
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Ionis Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Ionis Pharmaceuticals, Inc. is a pioneering commercial-stage biotechnology company specializing in the discovery and development of RNA-targeted medicines, headquartered in Carlsbad, California. Founded in 1989 by Stanley Crooke as ISIS Pharmaceuticals and renamed Ionis in December 2015, the publicly traded company has established itself as an indu... Read More
